Reading NRXS? Track it free: the weekly brief, plus an alert if the thesis breaks. No credit card.
Track NRXS free→Reading NRXS? Track it free: the weekly brief, plus an alert if the thesis breaks. No credit card.
Track NRXS free→QuarterlyIQ Insights · NRXS
Material updates from SEC filings (8-K, 10-Q, 10-K) ranked by impact, with no firehose noise.
Other Events. As previously disclosed, on August 29, 2025, the Company entered into an At The Market Offering Agreement (the “Agreement”) with Craig-Hallum Capital Group LLC (the “Sales Agent”) under which the Company may offer and sell, from time to time at its sole discretion, shares of its $0.001 par value common stock (the “Common Stock”), having an aggregate offering price of up to $6,270,000, through the Sales Agent as its sales agent. Pursuant to the Agreement, sales of the Common Stoc…
Results of Operations and Financial Condition On April 21, 2026, Neuraxis, Inc. (the “Company”), issued disclosure that, on a preliminary unaudited basis, the Company expects its cash and cash equivalents to be approximately $7.1 million as of March 31, 2026. The Company expects its net sales to be approximately $1.6 million for the three months ended March 31, 2026, as compared to approximately $0.9 million for the three months ended March 31, 2025. On a preliminary unaudited basis, the Comp…
Other Events. FDA 510(k) Clearance NeurAxis, Inc. (“NeurAxis” or the “Company”) today announced that it has received U.S. Food and Drug Administration (the “FDA”) 510(k) clearance for its proprietary percutaneous electrical nerve field stimulation (“PENFS”) technology for the treatment of functional abdominal pain (“FAP”) associated with functional dyspepsia (“FD”), and FD related nausea symptoms, in patients aged 8 years and older. The FDA reviewed the clinical literature supporting the use…
Results of Operations and Financial Condition On October 23, 2025, Neuraxis, Inc. (the “Company”), issued disclosure that, on a preliminary unaudited basis, the Company expects its cash and cash equivalents to be approximately $4.4 million as of September 30, 2025. On a preliminary unaudited basis, the Company expects its net sales to be approximately $0.8 million, its gross profits to be approximately $0.7 million, and its operating loss to be approximately $2.1 million, for the three months…
Entry into a Material Definitive Agreement. On August 29, 2025, Neuraxis, Inc. (the “ Company ”) entered into an At The Market Offering Agreement (the “ Agreement ”) with Craig-Hallum Capital Group LLC (the “ Sales Agent ”) under which the Company may offer and sell, from time to time at its sole discretion, shares of its $0.001 par value common stock (the “ Common Stock ”), having an aggregate offering price of up to $3,300,000, through the Sales Agent as its sales agent. Pursuant to the Agr…
Termination of a Material Definitive Agreement. The information contained in
Entry into a Material Definitive Agreement. As previously disclosed, on April 9, 2020, Neuraxis, Inc. (the “ Company ”) entered into a license and collaboration agreement (the “ License and Collaboration Agreement ”) with Masimo Corporation (“ Masimo ”). Under the License and Collaboration Agreement, the Company granted Masimo an exclusive, fully paid-up, royalty-free license to certain specifically identified patents and trademarks in a limited field of use, in connection with the NSS-2 Brid…
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. On July 1, 2025, the compensation committee of the board of directors (the “ Board ”) of the Company adopted the Neuraxis, Inc. 2025 Employee Stock Purchase Plan (the “ Employee Stock Purchase Plan ”), effective as of the same date. While the Employee Stock Purchase Plan is already effective, stockholder approval must be obtained within 12 months o…
Entry Into a Material Definitive Agreement. On May 20, 2025, Neuraxis, Inc. (the “ Company ”) entered into a securities purchase agreement (the “ Purchase Agreements ”) with certain institutional investors, pursuant to which the Company agreed to sell to such investors 1,538,461 shares (the “ Shares ”) of common stock of the Company, par value $0.001 per share (the “ Common Stock ”), at a purchase price of $3.25 per share of Common Stock (the “ Offering ”). The Shares were offered by the Comp…
Entry Into a Material Definitive Agreement. As previously disclosed, from February 2019 through July 2022, Ritu Bhambhani, M.D., Sudhir Rao, M.D., Ritu Bhambhani, LLC d/b/a Complete Care of Maryland; Box Hill Surgery Center, LLC, Pain and Spine Specialists of Maryland, LLC, SimCare ASC, LLC (together, the “ Releasing Parties ”) initiated lawsuits against the Company. As previously disclosed, the Company and Releasing Parties reached a tentative settlement on April 25, 2025. On May 15, 2025, t…
Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant. The information contained above in
General market headlines, full earnings-call transcripts, and macro and sector developments flagged when they directly affect this stock are on the way. Today this tab covers SEC filings.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.